Highlights
• Secured entire supply chain from cultivation through to distribution
-Received a manufacturing licence from the Office of Drug Control (ODC) enabling the cultivation, harvesting, manufacturing and distribution of cannabinoid medications in Australia
-Signed Heads of Agreement (HoA) with Australian Pharmaceutical Industries (ASX:API) for the distribution of AusCann’s medical cannabinoid products throughout Australia
-Prepared for import of cannabinoid medicines from Canopy Growth Corporation (TSE:WEED), North America’s largest producer of cannabinoid medicines
• Continued industry and government liaison
-Liaised with key opinion leaders within the medical profession, including many pain specialists
-Worked closely with government groups to advocate Australian patients having simpler access to high quality cost effective cannabinoid medicines
-AusCann stands to benefit from the Federal Government’s recent decision to allow cannabinoid medicines to be exported
• Progressed cultivation process
-Received second cultivation licence for Chile and planted second crop at 30-hectare Chilean facility
-Continued working closely with Tasmanian Alkaloids to plant first crop in Tasmania in the coming months
31 January 2018 – Leading medical cannabis company AusCann Group Holdings Limited (ASX:AC8) (AusCann or ‘the Company’) has today released its appendix 4C for the three-month period ended 31 December 2017 and is pleased to provide an overview of its activities for the quarter.
To view Report please download PDF attached:
Download this document
